Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Elias Zambidis

Elias Thomas Zambidis, M.D., Ph.D.

Assistant Professor of Oncology and Pediatrics
Associate Professor of Oncology

Male  | Languages: English, Greek

Appointment Phone

443-287-6997

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Assistant Professor of Oncology and Pediatrics
  • Associate Professor of Oncology
  • Assistant Professor of Pediatrics

Centers & Institutes

Departments

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 443-287-6997

401 N. Broadway
Charlotte R. Bloomberg Childrens Center
Baltimore, MD 21231 map
Fax: 410-955-0028

Contact for Research Inquiries

Phone: 443-287-2949

Expertise

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia , Hodgkin's Disease , Leukemia, Medical Oncology, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Pediatric Hematology-Oncology, Stem Cell Transplants

Featured Video

Elias Zambidis - Using Stem Cells to Study Cancer

    Additional Information

  • Education +

    Degrees

    • University of Rochester / M.D. Ph.D. (1998)

    Residencies

    • St Louis Children's Hospital / Pediatrics (2001)

    Fellowships

    • Johns Hopkins University School of Medicine / Pediatric Hematology & Oncology (2004)
  • Research & Publications +

    Research Summary

    The Zambidis lab is interested in the developmental biology of normal and malignant human stem cells. His group employs genetic manipulation and differentiation of human embryonic and induced pluripotent stem cells (iPSC) to study the cellular and molecular mechanisms of human hematopoiesis, vasculogenesis, and cardiogeneisis. Using human embryonic stem cells (hESC) derived from both normal and preimplantation genetic diagnosis (PGD)-screened embryos, as well as human iPSC, he is exploring how early mesodermal progenitors and human hemangioblast (bi-potential progenitor of hematopoietic stem cells (HSC) and endothelium) may give rise to the entire human hematopoietic and vascular systems, and whether such progenitors can be derived and expanded from differentiating human iPSC. His laboratory is studying the role of a variety of proteins and signaling molecules that are critically important in orchestrating the initiation of human embryonic hematopoiesis by directing the formation of human hemato-vascular progenitors in hESC and hiPSC. hESC/hiPSC-derived blood progenitors are also important in the understanding of the developmental origins of pediatric leukemia, but also for clinical HSC transplantation. Another major area of focus is determining the shared molecular circuits that regulate both malignant transformation and the maintenance of pluripotency. Applying these principles of shared biology between hematopoietic stem-progenitors and pluripotent stem cells, his group recently accomplished the creation of improved, highly efficient methods for generating nonintegrated, non-viral human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors that possess enhanced differentiation capacities and rapid loss of epigenetic memory. Additional projects include studying the developmental biology of gastrulation and cardiogenesis in model organisms and explores potential applications of pluripotent stem cell-derived cardiac in tissue engineering, regenerative medicine, cardiotoxicity screening and novel drug discovery.

    Lab:

    The Zambidis Lab

    Selected Publications

    1. Zambidis, E.T.; Oberlin, E.; Tavian, M.; Peault, B. Blood-forming endothelium in human ontogeny: lessons from in utero development and embryonic stem cell culture. Trends in cardiovascular medicine. 2006 Apr;16(3):95-101.
    2. Shah, N.; Zambidis, E.T. False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009 Jul;53(1):103-105.
    3. Ohm, J.E.; Mali, P.; Van Neste, L.; Berman, D.M.; Liang, L.; Pandiyan, K.; Briggs, K.J.; Zhang, W.; Argani, P.; Simons, B.; Yu, W.; Matsui, W.; Van Criekinge, W.; Rassool, F.V.; Zambidis, E.; Schuebel, K.E.; Cope, L.; Yen, J.; Mohammad, H.P.; Cheng, L.; Baylin, S.B. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 2010 Oct 1;70(19):7662-7673.
    4. Peters, A.; Burridge, P.W.; Pryzhkova, M.V.; Levine, M.A.; Park, T.S.; Roxbury, C.; Yuan, X.; Peault, B.; Zambidis, E.T. Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells. Int J Dev Biol. 2010;54(6-7):965-990.
    5. Pryzhkova, M.V.; Peters, A.; Zambidis, E.T. Erythropoietic differentiation of a human embryonic stem cell line harbouring the sickle cell anaemia mutation. Reprod Biomed Online. 2010 Aug;21(2):196-205.
  • Academic Affiliations & Courses +

    Graduate Program Affiliation

    Cellular and Molecular Medicine
    Immunology

  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.